Analysts Set MiniMed Group Inc (NASDAQ:MMED) Target Price at $22.45

Shares of MiniMed Group Inc (NASDAQ:MMED) have been given a consensus recommendation of “Moderate Buy” by the thirteen brokerages that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $22.4545.

Several brokerages recently issued reports on MMED. Evercore began coverage on shares of MiniMed Group in a report on Tuesday, March 31st. They set an “outperform” rating and a $20.00 target price for the company. Morgan Stanley began coverage on shares of MiniMed Group in a report on Tuesday, March 31st. They set an “overweight” rating and a $19.00 target price for the company. Barclays began coverage on shares of MiniMed Group in a report on Wednesday, April 1st. They set an “overweight” rating and a $26.00 target price for the company. Deutsche Bank Aktiengesellschaft began coverage on shares of MiniMed Group in a report on Tuesday, March 31st. They set a “buy” rating and a $20.00 target price for the company. Finally, Piper Sandler began coverage on shares of MiniMed Group in a report on Tuesday, March 31st. They set a “neutral” rating and a $16.00 target price for the company.

MiniMed Group Trading Down 2.1%

Shares of MiniMed Group stock opened at $12.92 on Friday. MiniMed Group has a 1 year low of $12.77 and a 1 year high of $20.48.

About MiniMed Group

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.